VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Organon & Co. $OGN

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 111,200 shares of the company's stock, valued at approximately $1,076,000.

Other institutional investors have also recently made changes to their positions in the company. Ransom Advisory Ltd purchased a new position in shares of Organon & Co. during the 1st quarter valued at $32,000. Hanson & Doremus Investment Management bought a new stake in shares of Organon & Co. during the 2nd quarter valued at $26,000. Brooklyn Investment Group raised its stake in shares of Organon & Co. by 1,012.3% during the 1st quarter. Brooklyn Investment Group now owns 3,070 shares of the company's stock valued at $46,000 after purchasing an additional 2,794 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Organon & Co. during the 1st quarter valued at $51,000. Finally, PARK CIRCLE Co raised its stake in shares of Organon & Co. by 640.7% during the 1st quarter. PARK CIRCLE Co now owns 4,000 shares of the company's stock valued at $60,000 after purchasing an additional 3,460 shares during the period. Hedge funds and other institutional investors own 77.43% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a "sell (d+)" rating on shares of Organon & Co. in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.33.

Organon & Co. Stock Performance

NYSE:OGN opened at $9.05 on Friday. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. Organon & Co. has a 52-week low of $8.01 and a 52-week high of $19.05. The firm has a market cap of $2.35 billion, a price-to-earnings ratio of 3.36, a PEG ratio of 0.81 and a beta of 0.63. The business's fifty day moving average is $9.92 and its 200 day moving average is $9.93.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The company's quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. Research analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Friday, August 15th were paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, August 15th. Organon & Co.'s dividend payout ratio is currently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.